drugset
drugset / Trial / NCT04128059

Study of Safety and Immunogenicity of BVRS-GamVac-Combi

NCT04128059 ↗

Phase 1/2 Unknown 268 enrolled Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation Acellena Contract Drug Research and Development · collab
RandomizedParallel-groupDouble-blindPrevention

Summary

The Middle East respiratory syndrome coronavirus (MERS-CoV) was identified in 2012 during the first Middle East respiratory syndrome (MERS) outbreak. MERS-CoV causes an acute lower-respiratory infection in humans, with a fatality rate of \~34.5%. The aim of the study is to assess the safety and immunogenicity of heterologous adenoviral-based vaccine against MERS - BVRS-GamVac-Combi.

Timeline

Start
2019-11-06
Primary completion
2021-07-01
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject BVRS-GamVac-Combi Vaccine — Intramuscular

Indications

Middle East respiratory syndrome